Affimed Gmbh

Amphivena Therapeutics, Inc.

Affemed Gmbh

Affirmed Gmbh

Affimed Therapeutics, Ag

Ivica Fucek

Uwe Reusch

Kristina Ellwanger

Erich Rajkovic

Stefan Knackmuss

Michael Weichel

Martin Treder

Melvyn Little

Eugene Zhukovsky

Thorsten Ross

Vera Molkenthin

Luke Evnin

Jeanmarie Guenot

Lori Kunkel

Judith A Fox

Michael Tesar

Claudia Wall

Michael Kluge

Michael Damrat

Joachim Koch

Markus Eser

Fionnuala McAleese-Eser

Thomas Mueller

Fionnuala Mcaleese-Eser

Eugene Zhukovksy

The invention relates to a multispecific antigen-binding molecule specifically binding to CD16A and consisting of two polypeptide chains, wherein each polypeptide chain comprises at least four variable domains from the N-terminus to the C-terminus in the order: VH_BCMA-VL_CD16A-VH_CD16A-VL_BCM.

Tandem diabody for CD16A-directed NK-cell engagement

Described are tetravalent, bispecific EGFR/CD16A antigen-binding proteins for engaging NK-cells towards EGFR-positive cells. EGFR/CD16A antigen-binding proteins with different pharmacokinetic (PK) properties are described. Further described is the use of bispecific EGFR/CD16A antigen-binding proteins for the treatment of an EGFR-positive malignancy, such as EGFR-positive tumors.

Bispecific EGFR/CD16 antigen-binding protein

The application pertains to a trispecific antibody molecule which may comprise a diabody-unit integrated into a polypeptide chain having at least six variable domains linked one after another. In certain instances two single-chain Fv (scFv) fragments are distally connected to the diabody-unit providing two further antigen binding sites (FIGS.and).

Multivalent FV antibodies

The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (Fc&#x3b3;RIIIA) expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.

NK cell engaging antibody fusion constructs

Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33cancers, diseases and conditions such as acute myeloid leukemia (AML).

Bispecific CD33 and CD3 binding proteins

This application describes binding proteins that specifically bind to EGFRvIII and multispecific binding proteins that specifically bind to EGFRvIII and CD3. Further described is a multispecific tandem diabody that binds to EGFRvIII and CD3. Further described are highly cytotoxic EGFRvIII/CD3 bispecific tandem diabody for recruiting T cells to specifically and potently kill several types of solid tumor cancer.

Antibody binding sites specific for EGFRvIII

The invention relates to a humanized CD3 binding site, which comprises (a) a variable heavy chain domain (VH) as depicted in SEQ ID NO:8 and a variable light chain domain (VL) as depicted in SEQ ID NO:3; or (b) a variable heavy chain domain (VH) as depicted in SEQ ID NO:9 and a variable light chain domain (VL) as depicted in SEQ ID NO:4, or c) a variable heavy chain domain (VH) as depicted in SEQ ID NO:7 and a variable light chain domain (VL) as depicted in SEQ ID NO:2; or (d) a variable heavy chain domain (VH) as depicted in SEQ ID NO:6 and a variable light chain domain (VL) as depicted in SEQ ID NO:1. The CD3 binding sites have an increased stability, while the binding affinity has been retained due to mutations at positions VH111 and VL49.

CD3 binding domains

Growing community of inventors

Frankfurt-am-Main, Germany

Ivica Fucek